SEARCH

SEARCH BY CITATION

References

  • 1
    Anthes JC, Richard C & West RE, et al. Functional characterization of desloratadine and other antihistamines in human H1 receptors. Allergy 2000;55 Suppl 63:S279 (Abstract 994).
  • 2
    Kreutner W, Hey JA, Anthes J, Barnett A, Young S & Tozzi S. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergic effects. Arzneimittelforschung 2000;50:345352.
  • 3
    Kreutner W, Hey JA, Anthes J, Barnett A & Tozzi S. Preclinical studies of desloratadine, a non-sedating, selective histamine H1 receptor antagonist with antiallergic activity. Allergy 2000;55 Suppl 63:S278 (Abstract 997).
  • 4
    He S & Walls AF. Human mast cell tryptase: a stimulus for microvascular leakage and mast cell activation. Eur J Pharmacol 1997;328:8997.DOI: 10.1016/s0014-2999(97)83033-6
  • 5
    Bisgaard H, Olsson P & Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986;16:289297.
  • 6
    Borish L & Joseph BZ. Inflammation and the allergic response. Med Clin North Am 1992;76:765787.
  • 7
    Yamaguchi YT, Suda J & Suda M, et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988;167:4356.
  • 8
    Kotsimbos TC, Ernst P & Hamid QA. IL-13 and IL-4 are co-expressed in atopic asthma. Proc Assoc Am Phys 1996;5:368373.
  • 9
    Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995;15:121129.
  • 10
    Denburg JA. Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Immunol Today 1999;20:111113.DOI: 10.1016/s0167-5699(98)01423-6
  • 11
    Henz BM, Maurer M, Lippert U, Worm M & Babina M. Mast cells as initiators of immunity and host defense. Exp Dermatol 2001 (in press).
  • 12
    Alam R, Stafford S & Forsythe O, et al. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993;150:34423447.
  • 13
    Teran C. Chemokines and IL-5: major players in eosinophil recruitment in asthma. Clin Exp Allergy 1999;29:287290.DOI: 10.1046/j.1365-2222.1999.00522.x
  • 14
    Nickel R, Beck LA, Stellato C & Schleimer RP. Chemokines and allergic disease. J Allergy Clin Immunol 1999;104:723742.
  • 15
    Lippert U, Artuc M & Grützkau A, et al. Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol 1998;161:26002608.
  • 16
    Canonica GW. Adhesion molecules in allergy. J Investig Allergol Clin Immunol 1997;7:274276.
  • 17
    Kleine-Tebbe J, Josties C & Frank G, et al. Inhibition of IgE-mediated and IgE-independent histamine release from human basophil leukocytes in vitro by H1-antagonist, descarbo-ethoxy-loratadine. J Allergy Clin Immunol 1994;93:494500.
  • 18
    Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G & Marone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27:559567.
  • 19
    Lippert U, Möller A, Welker P, Artuc M & Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000;9:118124.
  • 20
    Lippert U, Kruger-Krasagakes S, Möller A, Kiessling U & Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4:272276.
  • 21
    Molet S, Gosset P, Lasalle P, Czarlewski W & Tonnel AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997;27:11671174.
  • 22
    Lebel B, Bousquet J, Czarlewski W & Campbell AM. Loratadine reduces RANTES release by an epithelial cell line. J Allergy Clin Immunol 1997;99 (S444):Abstract 1802.
  • 23
    Vignola AM, Crampette L & Mondain M, et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995;50:200203.
  • 24
    Agrawal DK, Berro A & Townley RG. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation. Allergy 2000;55 Suppl 63:S276 (Abstract 990).
  • 25
    Hermes B, Prochazka A-K, Haas N, Jurgovsky K, Sticherling M & Henz BM. Upregulation of tumor necrosis factor α and interleukin-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 1999;103:307314.
  • 26
    Hey JA, Barnett A, Iorio L, Chiu P & Kreutner W. Desloratadine: cardiovascular, central nervous system, renal and gastrointestinal safety profile of this nonsedating H1 antihistamine. Allergy 2000;55 Suppl 63:S278 (Abstract 996).
  • 27
    Kreutner Hey JA, Chiu P & Barnett A. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung 2000;50:441448.
  • 28
    Scharf M, Kay G, Rikken G, Danzig M & Staudiger H. Desloratadine has no effect on wakefulness or psychomotor performance. Allergy 2000;55 Suppl 63 (Abstract 1001).
  • 29
    Vuurman EFPM, Ramaekers JG, Rikken G & De Halleux F. Desloratadine does not impair actual driving performance: a 3-way crossover comparison with diphenhydramine and placebo. Allergy 2000;55 Suppl 63 (Abstract 945).
  • 30
    Salmun LM, Lorber R, Danzig M & Staudiger H. Desloratadine is safe and effective treatment for relief of seasonal allergic rhinitis. Allergy 2000;55 Suppl 63 (Abstract 960).
  • 31
    Herron JM, Padhi D & Affrime MB, et al. Desloratadine demonstrates dose proportionality/linear pharmacokinetics in healthy adults. Allergy 2000;55 Suppl 63 (Abstract 955).
  • 32
    Marino M, Glue P & Herron JM, et al. Lack of electrocardiographic effects of multiple high doses of desloratadine. Allergy 2000;55 Suppl 63 (Abstract 999).
  • 33
    Banfield C, Rosenberg M & Cohen A, et al. Race and gender do not affect the multiple dose pharmacokinetics and safety of desloratadine. Allergy 2000;55 Suppl 63 (Abstract 991).
  • 34
    Yap YG & Camm AJ. Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy 1999;29 Suppl 3:174181.
  • 35
    Paris DG, Parente TF, Bruschetta HR, Guzman E & Niarchos AP. Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 1994;12:636638.
  • 36
    Zimmermann M, Duruz H & Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992;13:10021003.
  • 37
    Affrime MB, Banfield C & Glue P, et al. Lack of electrocardiographic effects when desloratadine and ketoconazole are combined. Allergy 2000;55 Suppl 63 (Abstract 992).
  • 38
    Glue P, Banfield C & Statkevich P, et al. Maxwell S, Clement R. Lack of electrocardiographic interaction between desloratadine and erythromycin. Allergy 2000;55 Suppl 63 (Abstract 989).
  • 39
    Bailey DG, Malcom J, Arnold O & Spence JD. Grapefruit juice–drug interaction. Br J Clin Pharmacol 1998;46:101110.
  • 40
    Banfield C, Gupta S & Affrime M, et al. Grapefruit juice reduces the bioavailability of fexofenadine but not desloratadine. Allergy 2000;55 Suppl 63 (Abstract 702).
  • 41
    Wacher VJ, Wu CY & Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129134.
  • 42
    Cayen MN, Wang E, Casciano CN, Clement RP & Johnson WW. Effect of desloratadine on P-glycoprotein (P-gp) transport system (MDR1). Allergy 2000;55 Suppl 63 (Abstract 1009).
  • 43
    Gupta S, Padhi D & Banfield C, et al. The oral bioavailability of desloratadine is unaffected by food. Allergy 2000;55 Suppl 63 (Abstract 959).
  • 44
    Crumb Wj Jr, Wible B, Arnold DJ, Payne JP & Brown AM. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol 1995;47:18190.
  • 45
    Taglialatela M, Castaldo P & Pannaccione A, et al. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 1999;29 Suppl 3:182189.